In various cancer types, GPR65 inhibition may inadvertently promote pro-tumour phenotypes—either by driving compensatory metabolic reprogramming or by altering macrophage polarisation in a way that supports tumour growth under specific conditions. This evidence concerns the gene GPR65 and neoplasm.